To test the efficacy of a clinical CRS-managing therapy in this model, BRGSF-CBC mice were treated with anti-TNF-α antibody Infliximab, before receiving OKT3 injections (Supplementary Figure 4A). This evidence concerns the gene TNF and congenital rubella syndrome.